Pharmacogenomics: time to rethink its role in precision medicine

Ann Oncol. 2018 Feb 1;29(2):293-295. doi: 10.1093/annonc/mdx780.

Authors

J A Willis¹, E Vilar²

Affiliations

¹ Hematology and Oncology Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
² Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of GI Medical Oncology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: evilar@mdanderson.org.

No abstract available

Publication types

Comment

MeSH terms

Colonic Neoplasms
Colorectal Neoplasms
Genotype
Humans
Pharmacogenetics*
Precision Medicine*

Grants and funding

T32 CA009666/CA/NCI NIH HHS/United States